Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immunodeficiency Diseases01:25

Immunodeficiency Diseases

919
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
919
Tumor Immunotherapy01:27

Tumor Immunotherapy

491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
Humoral Immune Responses01:36

Humoral Immune Responses

72.2K
Overview
72.2K
Development of Immunocompetence01:22

Development of Immunocompetence

294
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
294
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

119
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
119
Immunological Memory01:23

Immunological Memory

557
Immunological memory, a pivotal pillar of the adaptive immune system, is responsible for the body's ability to remember and respond more swiftly and effectively to previously encountered pathogens. This remarkable feature is what makes vaccines so effective in preventing diseases.
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
557

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peanut oral immunotherapy at a single academic medical center using a volume-based approach with store-purchased peanut products.

The journal of allergy and clinical immunology. Global·2026
Same author

Eosinophilic Gastrointestinal Disease After Pediatric Organ and Bone Marrow Transplantation.

JGH open : an open access journal of gastroenterology and hepatology·2026
Same author

55-Year-Old Woman With Chronic Cough.

Mayo Clinic proceedings·2026
Same author

Dupilumab- and Mepolizumab-Induced Psoriasis After Treatment of HES/AERD.

Mayo Clinic proceedings·2025
Same author

Step Down From Scheduled Inhaled Corticosteroids (ICS) Plus As-Needed Fast-Acting Beta-Agonists (FABA) to As-Needed ICS/FABA: A Systematic Review and Meta-Analysis.

The journal of allergy and clinical immunology. In practice·2025
Same author

Systemic JAK inhibitors for treatment of cutaneous manifestations in a patient with SPINK5 variants: A case report and review of the literature.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology·2025
Same journal

Key factors in the diagnosis of sesame allergy in children.

Allergy and asthma proceedings·2026
Same journal

Immunoglobulin E-mediated pumpkin seed allergy in children: Case series and narrative review with a structured literature search.

Allergy and asthma proceedings·2026
Same journal

Predictors of delayed treatment-free remission with omalizumab in chronic spontaneous urticaria.

Allergy and asthma proceedings·2026
Same journal

The digital front door: A national analysis of U.S. allergy and immunology fellowship program web sites.

Allergy and asthma proceedings·2026
Same journal

The impact of dietary patterns on the risk of asthma in children.

Allergy and asthma proceedings·2026
Same journal

The alpha-gal syndrome: Understanding the role of tick bites, and the delays in severe anaphylaxis.

Allergy and asthma proceedings·2026
See all related articles

Related Experiment Video

Updated: Jun 12, 2025

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

8.2K

Immunoglobulin therapy for immunodeficiency.

Bridget E Wilson, Catherine M Freeman

    Allergy and Asthma Proceedings
    |September 19, 2024
    PubMed
    Summary
    This summary is machine-generated.

    Immunoglobulin replacement therapy (IRT) offers passive immunity via intravenous or subcutaneous routes. This review covers IRT

    More Related Videos

    Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay
    06:15

    Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay

    Published on: September 7, 2018

    9.4K
    Intralymphatic Immunotherapy and Vaccination in Mice
    07:33

    Intralymphatic Immunotherapy and Vaccination in Mice

    Published on: February 2, 2014

    23.1K

    Related Experiment Videos

    Last Updated: Jun 12, 2025

    Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
    10:35

    Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

    Published on: December 26, 2017

    8.2K
    Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay
    06:15

    Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay

    Published on: September 7, 2018

    9.4K
    Intralymphatic Immunotherapy and Vaccination in Mice
    07:33

    Intralymphatic Immunotherapy and Vaccination in Mice

    Published on: February 2, 2014

    23.1K

    Area of Science:

    • Immunology and Medicine

    Background:

    • Immunoglobulin replacement therapy (IRT) provides passive immunity for antibody deficiencies.
    • Available routes include intravenous (IVIG) and subcutaneous (SCIG) administration.
    • Route selection impacts dosage, frequency, benefits, and risks.

    Purpose of the Study:

    • To provide a comprehensive overview of immunoglobulin replacement therapy.
    • To discuss route-specific administration, adverse effects, and management strategies.
    • To review monitoring and vaccination guidelines for patients on IRT.

    Main Methods:

    • Literature review and synthesis of current knowledge on immunoglobulin therapy.
    • Discussion of clinical considerations for route selection and product choice.
    • Analysis of adverse effects, risk factors, and mitigation strategies.

    Main Results:

    • IVIG and SCIG differ in dosing, frequency, and administration convenience.
    • Patient comorbidities influence optimal immunoglobulin product selection.
    • Adverse effects are manageable with appropriate risk assessment and monitoring.

    Conclusions:

    • Route of administration and product composition are critical factors in IRT.
    • Understanding and managing adverse effects are essential for patient safety.
    • Standardized monitoring and vaccination protocols enhance therapeutic outcomes.